XZXia Zhang

Xia Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xia Zhang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Huihui Zhang

    School of Medical Technology and Translational Medicine, Hunan Normal University, 410000 Changsha, Hunan, China

    8 shared publications
  • Shangze Li

    School of Medicine, Chongqing University, Chongqing, China

    3 shared publications
  • Zihan Wang

    School of Medical Technology and Translational Medicine, Hunan Normal University, 410000 Changsha, Hunan, China

    3 shared publications
  • Liang Huang

    Department of Laboratory Medicine, Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University School of Medicine, Changsha, China

    2 shared publications
  • Xuanyu Liu

    School of Medical Technology and Translational Medicine, Hunan Normal University, Tongzipo Road, Changsha 410013, China

    2 shared publications
  • An-Qi Zhang

    Department of Laboratory Medicine, Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Hunan Normal University School of Medicine, Changsha, China

    1 shared publication

Latest Publications

  • Open Access

    PF-127 Hydrogel-Delivered hUCMSC-Exosomes Attenuate Endometrial Injury by Inhibiting Epithelial-Mesenchymal Transition

    by Liwei Bao, Li Li, Shengbin Tang, Yezi Tang, Zihan Wang, Jiaxi Tan, Huihui Zhang, Rushi Liu, Xia Zhang

    Background:Endometrial injury, often resulting from iatrogenic procedures or infections, can lead to fibrosis, adhesions, and infertility. Current therapies are inadequate for reversing fibrosis or restoring normal function. Mesenchymal stem cell-derived exosomes (MSC-exos) present therapeutic potential; however, their rapid clearance poses a challenge. The purpose of this study was to develop a thermosensitive Pluronic F-127 (PF-127) hydrogel for sustained intrauterine delivery of human umbilical cord MSC-derived exosomes (PF-127-hUCMSC-exos) and to evaluate its efficacy and underlying mechanisms in a rat model of ethanol-induced endometrial injury.Methods:A thermosensitive PF-127 hydrogel loaded with hUCMSC-exos was developed. Its retention and therapeutic effects were evaluated in a rat model of ethanol-induced endometrial injury. Comparisons were made among control, model, hydrogel treatment alone, and PF-127-hUCMSC-exos treatment. Mechanistic assessments included histological analysis, collagen deposition measurement, fertility testing, expression analysis of epithelial-mesenchymal transition (EMT) markers (E-cadherin, vimentin, β-catenin), transcriptomic analysis of exosome-treated primary rat endometrial stromal cells, and measurement of early growth response 2 (EGR2) mRNA and protein levels.Results:PF-127-hUCMSC-exos were detectable in the uterine cavity up to day 12, and this treatment significantly improved endometrial morphology, increased thickness and gland number, reduced collagen deposition, and partially restored fertility. Mechanistically, exosomes inhibited EMT by upregulating E-cadherin and downregulating vimentin and β-catenin. RNA-seq of exosome-treated rESCs identified 1173 differentially expressed genes, with enrichment in EMT-related pathways. EGR2, a pro-fibrotic transcription factor, was significantly downregulated at both mRNA and protein levels. EGR2 overexpression promoted cell migration, which was reversed by exosome treatment.Conclusions:PF-127-hUCMSC-exos hydrogel effectively repairs endometrial injury and restores fertility by inhibiting EMT, potentially via EGR2 downregulation. This cell-free strategy offers a promising approach for endometrial regeneration.

  • Open Access

    IL-37 Ameliorates Chronic Endometritis by Attenuating Epithelial—Mesenchymal Transition and Promoting M2 Macrophage Polarization

    by Zihan Wang, Jiaxi Tan, Rui Zhang, Xuanyu Liu, Huihui Zhang, Xia Zhang

    Interleukin-37 (IL-37) is an anti-inflammatory cytokine with an undefined role in chronic endometritis (CE). This study aims to explore its therapeutic mechanism in CE, focusing on epithelial-mesenchymal transition (EMT) and macrophage polarization. A CE model was induced in Sprague-Dawley rats using lipopolysaccharide (LPS), followed by intervention with TAT-fused recombinant IL-37. Histological damage and fibrosis were evaluated through H&E and Masson staining. Immunofluorescence staining was performed to assess the expression of IL-37 and EMT markers (E-cadherin and vimentin) and macrophage phenotypes (M1: CD86+; M2: CD206+). In vitro, transwell, qPCR, Western blot, and flow cytometry analyses were performed to determine the effects of IL-37 on EMT and macrophage polarization. The activity of the STAT6 and Smad3 pathways was evaluated using Western blotting, dual-luciferase assays, and immunofluorescence staining. The results revealed that IL-37 accumulated in the injured uterus, alleviating inflammation, tissue damage, and collagen deposition. IL-37 reduced epithelial migration and reversed abnormal EMT by upregulating E-cadherin expression and downregulating vimentin expression. It also suppressed M1 macrophage infiltration and promoted M2 polarization. Mechanistically, IL-37 coactivated the STAT6 and Smad3 pathways, thereby increasing their phosphorylation and nuclear translocation and elevating ARG1 expression. In conclusion, IL-37 mitigates CE by suppressing EMT and promoting M2 macrophage polarization via coordinated STAT6/Smad3 activation, highlighting its therapeutic potential for CE.

  • Open Access

    IL-37 Ameliorates Chronic Endometritis by Attenuating Epithelial-Mesenchymal Transition and Promoting M2 Macrophage Polarization

    by Zihan Wang, Jiaxi Tan, Rui Zhang, Xuanyu Liu, Huihui Zhang, Xia Zhang

    Interleukin-37 (IL-37) is an anti-inflammatory cytokine with an undefined role in chronic endometritis (CE). This study explored its therapeutic mechanism in CE, focusing on epithelial-mesenchymal transition (EMT) and macrophage polarization. A rat model of CE was induced in Sprague-Dawley rats using lipopolysaccharide (LPS), followed by intervention with recombinant IL-37. Histological damage and fibrosis were evaluated via H&E and Masson staining, while immunofluorescence localized IL-37 and assessed EMT markers (E‑cadherin, Vimentin) and macrophage phenotypes (M1: CD86⁺; M2: CD206⁺). In vitro, transwell, qPCR, Western blot, and flow cytometry analyzed IL-37’s effects on EMT and macrophage polarization. STAT6 and Smad3 pathways were examined using Western blot, dual-luciferase assays, and immunofluorescence. Results showed IL-37 accumulated in injured uterus, alleviating inflammation, tissue damage, and collagen deposition. IL-37 reduced epithelial migration and reversed abnormal EMT by upregulating E-cadherin and downregulating Vimentin. It also suppressed M1 macrophage infiltration and promoted M2 polarization. Mechanistically, IL-37 co-activated STAT6 and Smad3 pathways, enhancing their phosphorylation and nuclear translocation, thereby increasing ARG1 expression. In conclusion, IL-37 mitigates CE by suppressing EMT and promoting M2 macrophage polarization via coordinated STAT6/Smad3 activation, highlighting its therapeutic potential for CE.

  • PDCD4: A critical regulator in leukemic signaling networks and its therapeutic potential

    by Jiaying Huang, Miao Yin, Ran Zhang, Yu Xia, Xia Zhang

    Programmed cell death 4 (PDCD4) is a tumor suppressor characterized by its MA3 domain-mediated binding to eIF4A, which suppresses protein synthesis. Its primary functions include inhibiting cell proliferation, invasion, and metastasis, as well as promoting apoptosis. Leukemia is a clonally hematologic malignancy whose pathogenesis is driven primarily by the aberrant activation of key signaling pathways. These dysregulated signals promote enhanced self-renewal, uncontrolled proliferation, impaired differentiation, and blocked apoptosis, collectively arresting leukemic cells at various stages of development. Recent studies have demonstrated a close association between PDCD4 and leukemia development, indicating that PDCD4 regulates this process mainly by participating in abnormally activated signaling pathways. This review examines the expression and regulation of PDCD4 in leukemia, with a focus on its role as a molecular hub that connects the JAK/STAT, PI3K/AKT, and MAPK signaling pathways into a comprehensive network of leukemia pathways. Furthermore, the potential value of PDCD4 in the treatment of leukemia is discussed.


  • Open Access

    USP5 Suppresses Ferroptosis in Bladder Cancer Through Stabilization of GPX4

    by Caiying Liu, Yanong Deng, Liang Huang, Xinrui Nie, Yuxuan Jiang, Xia Zhang, Huihui Zhang

    USP5 has been proven to play an important role in the proliferation of bladder cancer (BC). In this study, we focused on investigating the molecular mechanism of ferroptosis induced by USP5 in bladder cancer. The role of USP5 in bladder cancer was evaluated using T24 wild-type cells (WT) and USP5 knockout (USP5−/−) by CCK8 and colony formation assays. The contents of ferrobivalent ions (Fe2+), reactive oxygen species (ROS), and malondialdehyde (MDA) were detected using a determination kit to observe the relationship between USP5 and ferroptosis. Furthermore, the molecular mechanism study was evaluated by employing Western blotting, co-immunoprecipitation, RT-qPCR, ubiquitination assays, etc. This study showed genetic ablation of USP5 significantly inhibited the viability and proliferation of bladder cancer cells. Genetic ablation of USP5 promoted increases in Fe2+ content, ROS, and MDA levels. The addition of erastin significantly increased the viability and proliferation of T24 USP5−/− cells and significantly increased their ROS and MDA contents. We verified that USP5 deficiency led to a significant reduction in GPX4 protein levels and that the overexpression of USP5 could stabilize the GPX4 protein. Further studies showed that USP5 interacts with GPX4 and stabilizes GPX4 by inhibiting its ubiquitination These findings revealed USP5 inhibits ferroptosis in bladder cancer cells by stabilizing GPX4. The relationship between USP5 and ferroptosis could be a potential therapeutic target for bladder cancer.


  • Mesenchymal stem cells in injury repair of vital organs: from mechanism to clinical application

    by Liwei Bao, Zihan Wang, Li Li, Shengbin Tang, Guang Zhao, Huihui Zhang, Xia Zhang

    Mesenchymal stem cells (MSCs) are a type of pluripotent stem cells originating from the mesoderm, known for their capability to differentiate into various specific tissue cell types and fulfill corresponding physiological roles. Furthermore, MSCs are essential in modulating the tissue microenvironment through the release of soluble factors that can modify the local inflammatory conditions of injured tissues. As a result, MSCs show considerable promise for therapeutic use in a range of traumatic scenarios, including but not limited to liver damage, myocardial infarction, neurological conditions, lung trauma, kidney injuries, and disorders affecting the female reproductive system. They play a key role in alleviating cell apoptosis, sustaining cell survival, encouraging proliferation, enhancing the inflammatory milieu, minimizing tissue fibrosis, and supporting vascular regeneration. These mechanisms are crucial for controlling excessive and persistent inflammatory reactions that arise after organ injury, which may lead to cell death and hindered blood circulation, ultimately causing fibrosis and weakened organ functionality. Additionally, MSCs are gradually being incorporated into clinical settings, where careful considerations regarding methods of administration, dosing, safety, and effectiveness are vital for achieving optimal clinical results. This review provides an overview of the mechanisms by which mesenchymal stem cells aid in the repair of major bodily organs. We also examine their current status, obstacles, and pertinent issues concerning clinical applications.


  • Open Access

    Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing c-MYC

    by Xia Zhang, Peng Peng, Li-Wei Bao, An-Qi Zhang, Bo Yu, Tao Li, Jing Lei, Hui-Hui Zhang, Shang-Ze Li

    Background: Ubiquitination is an important post-transcriptional modification crucial for maintaining cell homeostasis. As a deubiquitination enzyme, ubiquitin-specific protease 1 (USP1) is associated with tumor progression; however, its role in bladder cancer is unknown. This study aimed to analyze USP1 expression and study its roles in bladder cancer. Methods: The web server GEPIA was used to analyze the USP1 expression. To explore USP1’s function in bladder cancer, we constructed USP1-knockout cell lines in UMUC3 cells. A FLAG-USP1 (WT USP1) plasmid and a plasmid FLAG-USP1 C90S (catalytic–inactive mutant) were used to overexpress USP1 in T24 cells. CCK8, colony formation, and Transwell assays were used to assess cell viability, proliferation, and migration. RNA-sequencing (RNA-seq) and dual-luciferase reporter assays were performed to screen the pathway. Co-immunoprecipitation and immunofluorescence were used to explore the interaction between USP1 and c-MYC. A xenograft mouse model was used to study the role of USP1 in bladder cancer. Results: USP1 expression was upregulated in human bladder cancer cells and correlated with poor patient prognosis. USP1 overexpression promoted cell proliferation, clone formation, and migration, and this was attenuated by genetic ablation of USP1. Furthermore, we observed that USP1 deficiency inhibited tumor formation in vivo. Mechanistically, the c-MYC pathway was remarkably activated compared with the other pathways. Furthermore, USP1 could interact with c-MYC and increase c-MYC’s stability depending on the catalytic activity of USP1. Conclusions: Our results suggested that high expression of USP1 promotes bladder cancer progression by stabilizing c-MYC; hence, USP1 may serve as a novel therapeutic target for treating bladder cancer.


  • Open Access

    Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression by Stabilizing C-myc

    by Xia Zhang, Peng Peng, Li-Wei Bao, An-Qi Zhang, Bo Yu, Tao Li, Jing Lei, Hui-Hui Zhang, Shang-Ze Li

    Background: Ubiquitination is an important post-transcriptional modification crucial for maintaining cell homeostasis. As a deubiquitination enzyme, ubiquitin-specific protease 1 (USP1) is associated with tumor progression; however, its role in bladder cancer is unknown. This study was aimed to analyze USP1 expression and study its roles in bladder cancer. Methods: The web server GEPIA was used to analyze the USP1 expression. To explore USP1 function in bladder cancer, we constructed USP1-knockout cell lines in UMUC3 cells. A FLAG-USP1 (WT USP1) plasmid and a plasmid FLAG-USP1 C90S (catalytic-inactive mutant) used to overexpress USP1 in T24 cells. CCK8, colony formation, and transwell assays were used to assess cell viability, proliferation and migration. RNA sequencing (RNA-seq) and dual-luciferase reporter assays were performed to screen the pathway. Coimmunoprecipitation and immunofluorescence were used to explore the interaction between USP1 and c-MYC. Xenograft mouse model was used to study the role of USP1 in bladder cancer. Results: USP1 expression is upregulated in human bladder cancer cells and correlated with poor patient prognosis. USP1 overexpression promoted cell proliferation, clone formation, and migration; this was attenuated by genetic ablation of USP1. Furthermore, we observed that USP1- deficiency inhibited tumor formation in vivo. Mechanistically, the c-MYC pathway was remarkably activated compared with the other pathways. Furthermore, USP1 could directly interact with c-MYC. and increase c-MYC stability depending on the catalytic activity of USP1. Conclusions: Our results suggest that high expression of USP1 promotes bladder cancer progression by stabilizing c-MYC; hence, USP1 it may serve as a novel therapeutic target for treating bladder cancer.


  • Open Access

    USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein

    by Hui-Hui Zhang, An-Qi Zhang, Peng Peng, Liang Huang, Cai-Ying Liu, Xin-Rui Nie, De-Fu Hou, Xia Zhang, Shang-Ze Li

    Background: Bladder cancer is the second most common genitourinary malignancy worldwide. The death rate of bladder cancer has increased every year. However, the molecular mechanism of bladder cancer is not sufficiently studied. Deubiquitinating enzymes (DUBs) play an important role in carcinogenesis. Several studies have demonstrated that USP5 associated with malignancy and pathological progression in hepatocellular carcinoma, colorectal and non-small cell lung cancer. However, the role of USP5 in bladder cancer need to be explored. Methods: The USP5 expression was analysed using the web server GEPIA. To explore USP5 function in bladder cancer, we constructed USP5-knockout cell lines in T24 cells. A FLAG-USP5 (WT USP5) plasmid and a plasmid FLAG-USP5 C335A (catalytic-inactive mutant) used to overexpress USP5 in EJ cells. CCK8, colony formation, transwell and scratch assays were used to assess cell viability, proliferation and migration. RNA sequencing (RNA-seq) and dual-luciferase reporter assays were performed to screen the pathway. Coimmunoprecipitation and immunofluorescence were used to explore the interaction between USP5 and c-Jun. Cycloheximide (CHX) chase assays were performed to establish the effect of USP5 on c-Jun stability. Xenograft mouse model was used to study the role of USP5 in bladder cancer. Results: USP5 expression is increased in bladder cancer patients. Genetic ablation of USP5 markedly inhibited bladder cancer cell proliferation, viability, and migration both in vitro and in vivo. RNA-seq and luciferase pathway screening showed that USP5 activated JNK signalling, and we identified the interaction between USP5 and c-Jun. USP5 was found to activate c-Jun by inhibiting its ubiquitination. Conclusions: Our results show that high USP5 expression promotes bladder cancer progression by stabilizing c-Jun and that USP5 is a potential therapeutic target in bladder cancer.


  • Open Access

    Identification of potential prognostic markers for lung adenocarcinoma using comprehensive analysis

    by Liang Huang, Anqi Zhang, Chunyan Tang, Jinmei Wei, Miao Li, Shishan Yuan, Huihui Zhang, Xia Zhang

    Lung adenocarcinoma (LUAD) is a common malignancy throughout the world with high levels of mortality and morbidity. In the present study, potential biomarkers and treatment targets for LUAD were investigated using data from The Cancer Genome Atlas. Overall, 4,485 differentially expressed genes (DEGs) were identified (1,857 upregulated and 2,628 downregulated) between tumor and adjacent control tissues. Functional analysis with Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Gene Set Variation Analysis and Gene Set Enrichment Analysis revealed significant enrichment of the DEGs in pathways related to system development, cell cycle and cell adhesion. Weighted gene co‑expression network analysis distinguished ten co‑expression modules on inclusion of the clinical profiles of patients with LUAD. Of these, the blue/turquoise modules showed peak association with tumor onset. Analysis of hub modules identified five hub genes, namely ANGPTL7, SLC6A4, PTPRQ, KCNA4 and TEDC2 (also known as C16orf59). Survival analysis revealed associations between hub‑gene expression profiles and patient prognosis. Downregulation of SLC6A4 in LUAD tumor tissues was confirmed using immunohistochemistry. Additional assays (Cell Counting Kit‑8, colony formation, scratch assay, cell cycle, Transwell invasion assay and cell adhesion assay) revealed that SLC6A4 overexpression inhibited A549 cell growth, invasion and migration. The findings demonstrated that the hub genes could act as treatment targets or new biomarkers for LUAD.